Benefits seen with femoral condylar osteochondral allografts treated with autogenous BMC
At 6 months postoperatively, investigators found superior radiographic bone integration and less sclerosis for femoral condyles that underwent transplantation with osteochondral allografts treated with autogenous bone marrow aspirate concentrate.
“This clinical outcomes study adds to the basic science and translational evidence supporting the use of autogenous bone marrow aspirate concentrate for enhancing osteochondral allograft bone healing to improve success for patients receiving [osteochondral allografts] OCA transplants,” James L. Cook, DVM, PhD, from the department of orthopaedic surgery at the University of Missouri School of Medicine, told Healio.com/Orthopedics.
Cook and colleagues used a prospective registry to identify patients treated with transplantation of large OCAs to one or both femoral condyles. There were 15 patients (17 condyles) who underwent transplantation without bone marrow aspirate concentrate and 22 patients (29 condyles) treated with bone marrow aspirate concentrate. An independent musculoskeletal radiologist who was blinded to the treatment group and assessed the condyles. Investigators assessed graft integration and degree of sclerosis at each time point.
Results showed that at 6 weeks, 3 months and 6 months postoperatively, patients treated with bone marrow aspirate concentrate had significantly better graft integration scores than patients who did not receive the bone marrow aspirate treatment. At 6 weeks and 3 months, patients treated with bone marrow aspirate concentrate had less graft sclerosis; however, this difference was not significant at 6 months. Groups were combined to determine the impact of smoking on graft integration, and investigators found nonsmokers had significantly greater graft integration than patients who smoked. – by Monica Jaramillo
Disclosure s : Cook reports he is a paid consultant for and receives royalties from Arthrex Inc. Please see the full study for a list of all other authors’ relevant financial disclosures.